Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) – Research analysts at Zacks Research decreased their Q3 2025 earnings per share estimates for shares of Corcept Therapeutics in a note issued to investors on Tuesday, January 21st. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings per share of $0.41 for the quarter, down from their prior estimate of $0.42. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ FY2025 earnings at $1.56 EPS.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $182.55 million during the quarter, compared to analysts’ expectations of $171.97 million. During the same quarter in the previous year, the company earned $0.28 EPS. The business’s quarterly revenue was up 47.7% compared to the same quarter last year.
Read Our Latest Stock Report on CORT
Corcept Therapeutics Stock Up 5.5 %
CORT opened at $62.29 on Friday. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $54.85 and its 200 day simple moving average is $45.44. Corcept Therapeutics has a 52 week low of $20.84 and a 52 week high of $62.98. The stock has a market cap of $6.53 billion, a PE ratio of 49.44 and a beta of 0.56.
Insider Transactions at Corcept Therapeutics
In related news, insider William Guyer sold 6,606 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $48.97, for a total value of $323,495.82. Following the sale, the insider now directly owns 5,796 shares of the company’s stock, valued at $283,830.12. This trade represents a 53.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.88, for a total value of $131,736.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,011 shares of company stock worth $1,951,268. Insiders own 20.50% of the company’s stock.
Institutional Trading of Corcept Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Capital Performance Advisors LLP bought a new position in Corcept Therapeutics in the 3rd quarter worth $25,000. Kathleen S. Wright Associates Inc. purchased a new stake in Corcept Therapeutics in the third quarter worth about $36,000. USA Financial Formulas bought a new stake in Corcept Therapeutics during the 4th quarter valued at approximately $54,000. GAMMA Investing LLC grew its holdings in shares of Corcept Therapeutics by 85.4% during the 3rd quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 1,147 shares during the period. Finally, KBC Group NV grew its holdings in shares of Corcept Therapeutics by 21.3% during the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 496 shares during the period. Hedge funds and other institutional investors own 93.61% of the company’s stock.
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Featured Articles
- Five stocks we like better than Corcept Therapeutics
- What is the S&P/TSX Index?
- Despite Short-Term Risks Freeport McMoran Worth a Look
- Most active stocks: Dollar volume vs share volume
- 3 Lean and Mean Stocks Generating Over $1M in Revenue Per Worker
- Want to Profit on the Downtrend? Downtrends, Explained.
- The Next Big Thing in AI: 2 Edge Computing Chipmakers to Watch
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.